Tygacil Warnings

FDA Announces New Warnings for IV Antibiotic due to Increased Risk of Death

by Norris Injury Lawyers | October 1st, 2013

October 1, 2013

Drug makers are responsible for testing and ensuring the safety of the medications they bring to market. The Alabama Drug Injury Lawyers with Norris Injury Lawyers explain that warning labels on drug packaging must state any dangers drugs pose to consumers.

In response to new findings that show the intravenous version of the antibiotic Tygacil (Tygecycline) may increase users’ risk of death, the FDA has ordered the makers of the drug to update the product’s warning label.

According to a press release from the agency, Tygacil is used to treat different types of serious skin infections, as well as intra-abdominal infections and community-acquired bacterial pneumonia. Experts say that the drug should not be used unless alternative treatment methods are unavailable or unsuitable for patients.

These recommendations were made after researchers discovered that those who use Tygecycline-based products have an increased risk of death of as much as four percent. These deaths were the result of infections worsening, complications caused by infections, or other medical conditions.

Norris Injury Lawyers’ team of Alabama Personal Injury Lawyers points out that warnings like this one highlight the need for more citizens to be aware of the side effects of drugs they take.